How Bad Are Biomedical Innovation Problems? Metrics Needed To Know For Sure
This article was originally published in The Pink Sheet Daily
Panel at Brookings Institution conference says there is no comprehensive measure and the issue is more complex than just tracking R&D spending and FDA approvals.
You may also be interested in...
FDA official says idea could be helpful; meanwhile, sponsors and others remain concerned about the framework’s undefined decision-making methods.
Trade organization may put its lobbying muscle behind ideas intended to lower trial costs and raise efficiency.
Venture capitalist suggests the agency should keep both issues in mind when it orders a sponsor to conduct more trials or submit additional data in order to bring down the cost of drug development.